What is Wedbush’s Estimate for RCKT Q4 Earnings?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Investment analysts at Wedbush issued their Q4 2024 earnings per share (EPS) estimates for Rocket Pharmaceuticals in a research note issued on Monday, December 30th. Wedbush analyst Y. Zhong anticipates that the biotechnology company will post earnings of ($0.67) per share for the quarter. Wedbush currently has a “Outperform” rating and a $32.00 target price on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.84) per share. Wedbush also issued estimates for Rocket Pharmaceuticals’ Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.60) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.32) EPS, FY2026 earnings at ($2.13) EPS, FY2027 earnings at ($1.93) EPS and FY2028 earnings at ($1.19) EPS.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group reissued a “buy” rating and set a $39.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Scotiabank started coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $50.00 target price for the company. Needham & Company LLC reissued a “buy” rating and issued a $52.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. Finally, Leerink Partners lowered their price target on Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Rocket Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $47.27.

Rocket Pharmaceuticals Stock Performance

Shares of NASDAQ:RCKT opened at $12.72 on Wednesday. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. Rocket Pharmaceuticals has a 1-year low of $11.15 and a 1-year high of $31.47. The stock has a market capitalization of $1.16 billion, a P/E ratio of -4.63 and a beta of 1.01. The business has a 50-day moving average price of $14.10 and a two-hundred day moving average price of $17.93.

Insider Transactions at Rocket Pharmaceuticals

In related news, CEO Gaurav Shah sold 11,091 shares of Rocket Pharmaceuticals stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $13.05, for a total transaction of $144,737.55. Following the completion of the transaction, the chief executive officer now owns 707,328 shares in the company, valued at approximately $9,230,630.40. This trade represents a 1.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 13,490 shares of company stock worth $176,045 in the last 90 days. Corporate insiders own 28.50% of the company’s stock.

Institutional Trading of Rocket Pharmaceuticals

A number of hedge funds have recently made changes to their positions in RCKT. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Rocket Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 582 shares during the period. Values First Advisors Inc. acquired a new position in shares of Rocket Pharmaceuticals in the third quarter valued at about $108,000. SG Americas Securities LLC bought a new position in Rocket Pharmaceuticals during the third quarter worth about $113,000. Dana Investment Advisors Inc. raised its stake in Rocket Pharmaceuticals by 4.4% in the 2nd quarter. Dana Investment Advisors Inc. now owns 13,847 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 586 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Rocket Pharmaceuticals in the 3rd quarter valued at about $286,000. 98.39% of the stock is owned by institutional investors and hedge funds.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.